K. G. Vanasse

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

H. Kantarjian, F. Ravandi, Koichi Takahashi, 2018, Blood.

The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

Shaji K. Kumar, M. Talpaz, A. Guenther, 2019, Leukemia.

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Hans Bitter, Franco Lombardo, Joseph Schoepfer, 2017, Nature.

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Yumin Dai, Yanchen Zhang, Mika K Lindvall, 2015, Journal of medicinal chemistry.

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

B. Druker, M. Heinrich, J. Cortes, 2019, The New England journal of medicine.

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

A. Jakubowiak, Shaji K. Kumar, E. Ocio, 2013 .

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

W. Sellers, F. Lombardo, W. Jahnke, 2014 .